Skip to main content
Clinical Trials/DRKS00028438
DRKS00028438
Not yet recruiting
Not Applicable

Observational study to evaluate the acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®) including patient who have been taken Slinda® for at least 5 cycles of use during breastfeeding. BreastSlinda® Study. - BREASTSLI-01-21

Exeltis Poland Sp.zo.o.0 sites100 target enrollmentMarch 2, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Exeltis Poland Sp.zo.o.
Enrollment
100
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 2, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Exeltis Poland Sp.zo.o.

Eligibility Criteria

Inclusion Criteria

  • 1\. Premenopausal women over 18 years of age
  • 2\. Women who used Slinda® for the authorized indication (contraception) and have
  • started treatment 5 cycles prior to the visit.
  • 3\. Women starting Slinda® from 4 weeks after delivery
  • 4\. Only Women who were breastfeeding.
  • 5\. Only Women who were taking continuously Slinda from week 4\-12 weeks (after delivery) but not longer that 8 months after delivery.
  • 5\. Women must give their informed consent to participate in the study.

Exclusion Criteria

  • 1\. Patients with contraindications stated in the summary of characteristics
  • 2\. Patients with severe, acute, or chronic disease (e.g., pancreatitis, liver disease,
  • genital tumors, severe renal insufficiency or acute renal failure, history of
  • hyperkalaemia, etc.) that clinically could interfere with the evaluation.
  • 3\. Gynecological pathologies such as endometriosis, myomatous uterus, or
  • polycystic ovary syndrome.
  • 4\. Coagulopathies or hematologic diseases.
  • 5\. Thromboembolic history.
  • 6\. Consumption of products such as medicinal plants that can induce microsomal
  • enzymes, especially cytochrome P450\.

Outcomes

Primary Outcomes

Not specified

Similar Trials